022dc727 C077 4611 8a3d 967ee99f9828 01
Topiramate
Product Images NDC 70934-420
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70934-420). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
022dc727 C077 4611 8a3d 967ee99f9828 02
This is a graph showing the cumulative rates for time to first seizure between two groups of patients. The first group consisted of 234 patients taking 50mg/day of topiramate, while the second group consisted of 236 patients taking 400mg/day of topiramate. The graph plots the time (in days) on the x-axis and the cumulative rate on the y-axis.*
022dc727 C077 4611 8a3d 967ee99f9828 03
The text describes the change from baseline for the average monthly migraine period rate for patients who were administered Topamax in the double-blind phase. The dosage for Topamax varied between 100mg/day and 200mg/day. The statistical significance of this change is also mentioned in terms of p-values.*
70934 420 30 Master Bottle Label Approval Rev A 08 19
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
